GoAI
Get started
Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.30

+$0.20 · +2.20%

Aug 21, 4:00 PM ET

SLDB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

34

Expensive

Momentum

70

Gaining

Sentiment

62

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Alexander G. Cumbo
Listed since
Jan 26, 2018
Employees
121

Market position

Day range

Current $9.30

52-week range

Current $9.30

Open
$9.34
Previous close
$9.10
Volume
790.37K
0.54× average
Average volume
1.45M
Average daily volume
Market cap
915.58M USD
Beta
2.42
Market reference 1
50-day average
$8.9151
+4.32% above average
200-day average
$7.0315
+32.26% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
454.79M USD
P/E (TTM)
-4.87×
P/B (TTM)
3.57×
P/S (TTM)
0×
EV / EBITDA
-2.63×
Earnings yield
-35.32%
Free cash flow yield
-31.90%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-96.84%
Return on assets
-74.97%
Return on invested capital
-89.08%

Financial health

Debt / equity
0.05×
Current ratio
6.14×
Altman Z-score
7.67
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends242%-325%-891%-1457%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -530.50%Operating margin, FY2022: -1315.20%Net margin, FY2021: -530.01%Net margin, FY2022: -1062.28%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -530.50%. Operating margin FY2022 -1315.20%. Net margin FY2021 -530.01%. Net margin FY2022 -1062.28%.

Income trends

Revenue

8.09M USD-40.57%

Operating income

−179.21M USD-38.14%

Net income

−174.33M USD-39.80%
Income trends across reported periods32.9M USD−44.23M USD−121.36M USD−198.49M USDRevenue, FY2021: 13.62M USDRevenue, FY2022: 8.09M USDOperating income, FY2021: −72.25M USDOperating income, FY2022: −106.45M USDOperating income, FY2023: −104.32M USDOperating income, FY2024: −129.73M USDOperating income, FY2025: −179.21M USDNet income, FY2021: −72.19M USDNet income, FY2022: −85.98M USDNet income, FY2023: −96.02M USDNet income, FY2024: −124.7M USDNet income, FY2025: −174.33M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.62M USD. Revenue FY2022 8.09M USD. Operating income FY2021 −72.25M USD. Operating income FY2022 −106.45M USD. Operating income FY2023 −104.32M USD. Operating income FY2024 −129.73M USD. Operating income FY2025 −179.21M USD. Net income FY2021 −72.19M USD. Net income FY2022 −85.98M USD. Net income FY2023 −96.02M USD. Net income FY2024 −124.7M USD. Net income FY2025 −174.33M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———8.09M USD13.62M USD
Cost of goods sold1.64M USD2.46M USD2.58M USD——
Gross profit−1.64M USD−2.46M USD−2.58M USD8.09M USD13.62M USD
Research and development140.33M USD96.43M USD76.56M USD78.42M USD58.74M USD
Selling, general, and administrative38.88M USD33.3M USD27.75M USD28.95M USD27.14M USD
Operating expenses177.57M USD127.27M USD101.73M USD114.55M USD85.87M USD
Interest income9.9M USD9.47M USD7.14M USD2.62M USD64K USD
Interest expense—340K USD———
Depreciation and amortization1.64M USD2.46M USD2.58M USD2.41M USD2.96M USD
Operating income−179.21M USD−129.73M USD−104.32M USD−106.45M USD−72.25M USD
Net income−174.33M USD−124.7M USD−96.02M USD−85.98M USD−72.19M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-4.52%
11 comparable reports
Latest EPS result
-0.38
Estimate -0.46 · Beat by 17.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.33-0.53-0.73-0.93Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.89, estimate -0.79, surprise -12.66%, Miss. Q2 2025, reported May 15, 2025: actual -0.59, estimate -0.53, surprise -11.32%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.42, estimate -0.51, surprise +17.65%, Beat. Q4 2025, reported Nov 3, 2025: actual -0.48, estimate -0.42, surprise -14.29%, Miss. Q1 2026, reported Mar 19, 2026: actual -0.5, estimate -0.51, surprise +1.96%, Beat. Q2 2026, reported May 12, 2026: actual -0.52, estimate -0.4, surprise -30.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.38, estimate -0.462, surprise +17.81%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate -0.37, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.02M3.69M2.36M1.03MQ1 '24No estimateQ2 '24Estimate
Q1 2024, reported Mar 13, 2024: actual 4.74M USD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported May 15, 2024: actual —, estimate 1.21M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.00

93.55% upside
Past 12 months12-month forecastHigh $20.00Average $18.00Low $16.00

Rating distribution

22 ratings
Strong buy00%
Buy1777%
Hold523%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
Truist SecuritiesmaintainBuy
CitigroupmaintainBuy

SLDB news

seekingalpha.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028,…

Read source
seekingalpha.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Read source
globenewswire.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today…

Read source
globenewswire.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today…

Read source
globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 28, 2022

1:15

SLDB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SLDB

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
25.38M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
24.67M
Weight
0.22%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
18.39M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.25M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
5.38M
Weight
0.05%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
4.43M
Weight
0.07%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.56M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.38M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research SLDB

research.disclaimer